In mCRC, primary tumor resection status may hint at bevacizumab efficacy

  • Cao D & al.
  • Sci Rep
  • 30 Dec 2019

  • curated by Jim Kling
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Bevacizumab is associated with better progression and survival outcomes in primary tumor-unresected and primary tumor-resected metastatic colorectal cancer (mCRC).
  • These authors find the results for resected tumor more convincing.

Why this matters

  • The study is the first meta-analysis to examine the association between primary tumor resection and survival among patients with mCRC treated with bevacizumab.

Study design

  • A meta-analysis of 7 studies (N=2760).
  • Funding: National Natural Science Fund of China; Natural Science Fund of Hubei Province.

Key results

  • Compared with patients whose primary tumor was not resected, patients whose primary tumor was resected (6 studies) had better:
    • OS: HR, 0.50 (P<.00001>
    • PFS: HR, 0.65 (P=.0002).
  • In patients with resected primary tumors, treatment with bevacizumab vs treatment with chemotherapy alone was associated with better:
    • OS (3 studies): HR, 0.65 (P<.00001>
    • PFS (2 studies): HR, 0.68 (P=.0001).
  • In patients with unresected primary tumors, treatment with bevacizumab compared with chemotherapy alone (2 studies) was associated with better:
    • OS: HR, 0.78 (P=.009).
    • PFS: HR, 0.71 (P=.002).
    • However, the significant OS benefit depended on results from a single study.

Limitations

  • 5 studies were retrospective, 2 prospective.